Michael Kalfas and Paul Leeks summarise a recent Danish study that assesses the risk of antidepressant-induced mania in patients with bipolar depression.
[read the full story...]
Steven Marwaha publishes his debut blog on a review article that asks if there is consensus across international evidence-based guidelines for the management of bipolar disorder.
[read the full story...]
Kathryn Walsh summarises a systematic review which finds that cannabis use may exacerbate symptoms of mania in those with a diagnosis of bipolar disorder, and trigger symptoms of mania in the general population.
[read the full story...]
There are a range of treatment options for people with bipolar disorder who are experiencing a manic episode. An important part of this treatment is to reduce the symptoms of mania and provide the individual with some level of normality. I blogged this time last year about a meta-analysis in the Lancet that showed that [read the full story…]
Aripiprazole (brand names Abilify and Aripiprex) is an atypical antipsychotic drug used to treat a number of mental health disorders including schizophrenia, depression and bipolar disorder. This new guidance has been written by a group of Pan-European experts who have come together to review new clinical guidelines for the management of mania and the role of aripiprazole [read the full story…]
Researchers from Oxford and Verona have published a major new meta-analysis in the Lancet, which measures the effectiveness of all anti-manic drugs. The review team searched and found 68 randomised controlled trials from 1980-2010 (a total of 16,073 patients). The study includes a range of antipsychotics and mood stabilisers used at a therapeutic dose range [read the full story…]
